

## **MARKET ANALYSIS OF DRUGS USED FOR THE TREATMENT OF CEREBRAL PALSY**

Ignatenko M.A., Kotvitska A.A., Kubaryeva I.V.

The National University of Pharmacy, Kharkiv, Ukraine

[socpharm@ukr.net](mailto:socpharm@ukr.net)

More than 14 thousand people of all ages suffer from cerebral palsy (CP) in Ukraine nowadays. The most important consequences of this disease are disability and reduction of life expectancy of patients. That's why the improvements of pharmaceutical help in terms of improving of its accessibility and adequacy are important medical and social problems.

In view of the above, the purpose of the study was to analyze the domestic market of drugs (LP) used for the treatment of cerebral palsy. We used the marketing and statistical research methods and the methods of scientific analysis, in particular, comparison, grouping, summarizing data.

According to the state social standards of medical care for patients with cerebral palsy, we have found that the main groups of drugs used for the treatment of cerebral palsy is anxiolytics, muscle relaxants, cardiotonic, antiparkinsonian, m- and n-cholinomimetics, nootropic, antihypoxants, vasodilators, anticholinergic agents,  $\alpha$  – blockers. According to the research of the pharmaceutical market of Ukraine for the period of 2011-2013, 32 trade names of drugs of ten groups were registered. Among these drugs 11 drugs are produced in Ukraine by the 6 companies and 21 drugs are produced in other countries by 19 manufacturers. In percentage, it is 34% and 66% respectively. The results of the study of the countries - manufacturers show that the number of firms and the drugs they propose are represented widely geographically. For example, drugs for the treatment of cerebral palsy are imported to Ukraine from 12 countries. The main importing countries are Poland and Austria, supplying 13% and 9% respectively of the total number of drugs for the treatment of cerebral palsy. Ireland, Hungary, USA and Germany export to Ukraine 2 drugs each that is 25%, France, Switzerland, Latvia, Slovenia, Spain, Italy – export 1 drugs each, it's 19%, respectively. Among domestic manufacturers the leading position occupies FC (Pharmaceutical Company "Zdorovye" ("Health") (5 products) and JSC "Farmak" (2 pills), representing 16% and 6% of registered drugs for the treatment of cerebral palsy, respectively.

Based on the above, it can be argued that the Ukrainian pharmaceutical market drugs for the treatment of cerebral palsy is characterized by significant dependence on imports and requires diversification of domestic production of drugs to enhance performance availability of drugs for patients with socially significant diseases, which include cerebral palsy.